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ABSTRACT
Tumor growth–generated mechanical compression may increase or decrease 
expression of microRNAs, leading to tumor progression. However, little is known 
about whether mechanical compression induces aberrant expression of microRNAs 
in cancer and stromal cells. To investigate the relationship between compression and 
microRNA expression, microRNA array analysis was performed with breast cancer 
cell lines and cancer-associated fibroblasts (CAFs) exposed to different compressive 
conditions. In our study, mechanical compression induced alteration of microRNA 
expression level in breast cancer cells and CAFs. The alteration was greater in the 
breast cancer cells than CAFs. Mechanical compression mainly induced upregulation of 
microRNAs rather than downregulation. In a parallel mRNA array analysis, more than 
25% of downregulated target genes were functionally involved in tumor suppression 
(apoptosis, cell adhesion, and cell cycle arrest), whereas generally less than 15% 
were associated with tumor progression (epithelial-mesenchymal transition, 
migration, invasion, and angiogenesis). Of all cells examined, MDA-MB-231 cells 
showed the largest number of compression-upregulated microRNAs. miR-4769-5p 
and miR-4446-3p were upregulated by compression in both MDA-MB-231 cells and 
CAFs. Our results suggest that mechanical compression induces changes in microRNA 
expression level, which contribute to tumor progression. In addition, miR-4769-5p 
and miR-4446-3p may be potential therapeutic targets for incurable cancers, such as 
triple negative breast cancer, in that this would reduce or prevent downregulation of 
tumor-suppressing genes in both the tumor and its microenvironment simultaneously.
INTRODUCTION
Tumor progression is associated with microRNA 
expression and signal transduction by tissue mechanics, 
or mechanotransduction [1]. However, little is known 
about the relationship between microRNA expression and 
mechanotransduction in tumor progression.
Tumor growth may induce aberrant expression 
of microRNA that leads to tumor progression via 
mechanotransduction. Mechanical stress, such as 
compression, tension, and interstitial fluid pressure, are 
expected to be increased by tumor growth, and thereby 
participate in tumor progression [2]. Indeed, increased 
compressive force was measured in the interior and 
periphery of tumors [3]. Compression-induced microRNA 
expression was previously reported in nontumor cells. 
In human periodontal ligament cells, expression of 
microRNA (miR)-29 is altered by compression [4]. miR-
222 expression is upregulated by compression in articular 
cartilage [5], and mechanical compression induces 
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upregulation of miR-146a in chondrocytes [6]. In breast 
cancer, miR-18a is mechanically upregulated by increased 
tissue stiffness [7], the major mechanical stress component 
of which is tension [8]. Whereas this finding does not 
constitute direct evidence to support compression-induced 
microRNA expression, it does support the possibility that 
tumor growth regulates microRNA expression level via 
compression.
Compromising compression-altered microRNAs 
may be a good option for cancer therapy. Aberrant 
expression of microRNAs is associated with tumor 
progression. Upregulation of miR-224 enhances tumor 
invasion and growth in non-small cell lung cancer by 
targeting SMAD4 and TNFα-induced protein 1 [9]. 
Upregulated miR-21 induces growth of hepatocellular 
cancer by modulating PTEN expression [10]. In breast 
cancer, miR-107 expression increases tumorigenesis 
and metastasis via inhibition of let-7 [11]. As a target 
for cancer therapy, the effect of microRNA modulation 
on tumor suppression has been validated in mouse 
models [12]. Uncontrolled proliferation is a fundamental 
characteristic of cancer cells [13]. Compression is 
likely one of the general stimuli leading to tumor 
progression [14]. Therefore, targeting compression-
altered microRNAs may be useful for the development 
of a therapy that is generally applicable to various 
cancer phenotypes. Recently, personalized therapy has 
been a focus of cancer research [15–17]. This approach 
is expected to be highly effective in removing cancer 
cells, with reduced side effects. However, high cost and 
longer duration of treatment are thought to be drawbacks 
of personalized therapy. In this regard, cancer therapy 
targeting microRNAs commonly altered by compression 
may be a good alternative approach. To develop such a 
generally applicable cancer therapy, different responses 
of cancer cells to compression must be examined because 
tumor heterogeneity is one of the main causes of drug 
resistance [18–20]. In addition, the responses should be 
further investigated under different compressive states, 
which reflect the variation in compression during tumor 
growth.
In this study, we present microRNA 
transcriptome-wide analyses of compression-induced 
alterations in microRNA expression level in breast 
cancer cell lines [MCF-7(luminal A: ER+, PR+, 
HER2), BT-474(luminal B: ER+, PR+, Her2+), SK-
BR-3(Her2: ER-, PR-, Her2+), MDA-MB-231(triple 
negative or Claudin-low: ER-, PR-, Her2-)] [21, 22] and 
cancer-associated fibroblasts (CAFs), a representative 
component of the tumor microenvironment, compressed 
at different relative compression units (RCUs). One 
RCU equals 5.8 mmHg (~0.773 kPa), which is the 
approximate compression value of a native tumor 
microenvironment [23]. To investigate whether 
compression-induced microRNA expression contributes 
to tumor progression, the target genes of microRNAs 
identified in the parallel mRNA array analysis were 
further evaluated by classifying as tumor suppression-
associated genes (TSAGs) and tumor promotion-
associated genes (TPAGs).
RESULTS
Compression-induced alteration of microRNA 
expression level in breast cancer
Mechanical stress induces microRNA expression, 
leading to changes in cell behavior [24, 25]. Because 
tumor growth generates mechanical compression that 
acts on cancer cells and adjacent stromal cells, microRNA 
expression profiles in breast cancer cells and CAFs may be 
altered by compression. To confirm whether compression 
modulates microRNA expression, with changes dependent 
on the degree of compression, microRNA expression was 
examined by microRNA array in four types of breast 
cancer cell lines and four cultures of CAFs isolated from 
individual invasive ductal carcinoma (IDC) patients. As 
shown in Figure 1A, microRNA expression was up- or 
downregulated by compression in breast cancer cell lines 
and CAFs. Compression-upregulated microRNAs were 
generally more abundant in breast cancer cell lines than 
in CAFs, particularly those upregulated by 2- to 10-fold. 
MicroRNAs upregulated by compression by greater than 
10-fold were similar among breast cancer cell lines and 
CAFs, with the exception of CAF1. CAF1 showed the 
lowest number of compression-upregulated microRNAs, 
whereas CAF2 showed the highest among CAFs (Figure 
1B). Compression-downregulated microRNAs were 
much smaller in number than compression-upregulated 
microRNAs (Figure 1C). Compression-induced 
alterations in microRNA expression level were different 
at each RCU, and were not proportional to the degree 
of compression. Thus, the microRNAs commonly up- 
or down-regulated by compression were analyzed to 
compare cell susceptibility to compression and to develop 
diagnostic markers or therapeutic targets for cancer 
therapy. The largest number of microRNAs commonly 
upregulated 2- to 10-fold by compression was observed 
in SK-BR-3 cells, with the second largest number seen 
in CAF2. By contrast, the largest number of microRNAs 
commonly upregulated by greater than 10-fold was 
observed in MDA-MB-231 cells (Figure 1D). Less than 
10 commonly downregulated microRNAs were seen in 
MCF7, MDA-MB-231, CAF1, CAF2, and CAF4 cells, 
and none were observed in BT-474, SK-BR-3, and CAF3 
cells (Figure 1E).
Analysis of cell-type–specific fold change in 
compression-upregulated microRNAs
MicroRNA expression level was regulated by 
compression in breast cancer cell lines and CAFs 
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(Figure 1A). Next, to understand how the degree of 
compression affects the level of microRNA expression, 
fold changes in expression of the microRNAs commonly 
upregulated by compression by greater than 10-fold 
were compared within six ranges of fold change: 0–49, 
50–99, 100–149, 150–199, 200–249, and 250–300. Fold 
change values of compression-upregulated microRNAs 
are shown in Supplementary Table S1. Commonly 
downregulated microRNAs were not compared because 
they were insufficient in number (Figure 1E). In BT-474 
cells, 12 microRNAs were upregulated by compression. 
MiR-671-5p, miR-4486, and miR-664b-5p showed the 
greatest fold increase, ranging from 100–199 (Figure 
2A). Nine microRNAs were seen in MCF7 cells. MiR-
4733-5p, miR-617, and miR-577 showed the greatest 
fold change, ranging from 100–149 (Figure 2B). In SK-
BR-3 cells, 41 microRNAs were upregulated by greater 
than 10-fold by compression. MiR-617, miR-644a-5p, 
miR-99b-3p, miR-628, miR-3p, and miR-3654 showed 
the greatest fold change, ranging from 100–199 (Figure 
2C). MDA-MB-231 cells showed the largest number 
(53) of compression-upregulated microRNAs among 
breast cancer cell lines. Interestingly, the fold change 
in microRNA expression level was generally higher 
at RCUs of 2, 5, and 10 than at 0.5 and 1 in MDA-
MB-231 cells, unlike other breast cancer cell lines, 
which showed similar fold change at all RCUs. MiR-
4486 showed the highest level of upregulation, ranging 
from 200–249 at RCUs of 5 and 10 (Figure 2D). In 
CAF1 cells, only three microRNAs were upregulated. 
MiR-4733-5p showed the largest fold increase, ranging 
from 150–199 (Figure 2E). CAF2 cells had the largest 
number of compression-upregulated microRNAs among 
CAFs (46) and the greatest fold increase among all 
cells examined. Fold change in expression levels of 
MiR-3127-5p, miR-1288, miR-1471, miR-4665-5p, 
miR-4538, and miR-513b in CAF2 ranged from 250–
300 (Figure 2F). In CAF3 cells, 21 microRNAs were 
upregulated by compression. MiR-1288, miR-450a-5p, 
and miR-4446-3p showed the greatest fold increase 
(Figure 2G). In CAF4 cells, 16 microRNAs were 
upregulated by compression. MiR-3138, miR-3127-
5p, and miR-5190 showed the greatest fold increase, 
ranging from 200–249 (Figure 2H). Simultaneously 
targeting cancer cells and the tumor microenvironment 
may be a good therapeutic strategy for currently 
incurable cancers, such as triple negative breast cancer: 
a heterogeneous group of breast cancer difficult to be 
treated by pre-existing chemotherapies for lacking 
estrogen receptor (ER), progesterone receptor (PR), 
and Her2/neu [26–29]. MiR-4769-5p and miR-4446-
3p were commonly upregulated by compression in the 
triple negative breast cancer cell line MDA-MB-231, 
as well as in CAF2, CAF3, and CAF4 cells (Figure 2I).
Figure 1: Compression-induced changes in microRNA expression level in breast cancer. A. Pattern analysis of compression-
induced microRNA expression level in breast cancer cells and cancer-associated fibroblasts (CAFs). Numerical comparison of B. 
compression-upregulated microRNAs, C. compression-downregulated microRNA, D. common compression-upregulated microRNAs 
at different compression conditions, and E. common compression-downregulated microRNAs at different compression conditions. For 
compression, 0 (control), 0.5, 1, 2, 5, or 10 RCUs were applied to cells for 24 h. BT, BT-474 cells; SK, SK-BR-3 cells; MDA, MDA-
MB-231 cells.
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Analysis of fold change in expression levels 
of the putative target genes of compression-
upregulated microRNAs
The compression-upregulated microRNAs are 
associated with a large number of target genes, as shown 
in Supplementary Figure S1. The primary function of 
microRNA is to suppress target mRNA expression. 
Therefore, the putative target genes of the compression-
upregulated microRNAs, which have more than 80 target 
prediction score (Supplementary Table S2) from miRDB 
(http://mirdb.org/miRDB), and the fold change values of 
the putative target mRNAs were analyzed by mRNA array 
using the same samples of total RNA used for microRNA 
array. Greater than 5-fold decrease was used as the cut-
off for target mRNA downregulation by microRNAs. In 
BT-474 cells, 19 target mRNAs were downregulated. 
Of these, eight were potential targets of miR-7-1-3p 
(TRHDE, FZD8, PCDH11Y, PMP2, TRDN, RNF180, 
LINGO2, and ROBO2). The most downregulated target 
mRNA was TSPAN7, a putative target of miR-4656 
(Figure 3A). In MCF7 cells, ZDHHC21 (a putative target 
of miR-4733-5p) and DCX (a putative target of miR-
663b) were downregulated (Figure 3B). SK-BR-3 cells 
showed downregulation of 53 target mRNAs. SLC35F1 
(a putative target of miR-551b-5p) was downregulated 
by approximately 80-fold. MPL (a putative target of 
miR6511a-5p), ONECUT2 (a putative target of miR-
4282), and TMEM98 (a putative target of miR-6511b-5p) 
were downregulated by approximately 40-fold (Figure 
3C). In MDA-MB-231 cells, 114 target mRNAs were 
downregulated. YPEL5 (a putative target of miR-4522) 
Figure 2: Analysis of cell-type–specific fold change in compression-upregulated microRNAs. Surface graph analysis of 
compression-upregulated microRNAs in A. BT-474, B. MCF7, C. SK-BR-3, D. MDA-MB-231, E. CAF1, F. CAF2, G. CAF3, and H. 
CAF4. I. MicroRNAs commonly upregulated by compression in MDA-MB-231 cells and CAFs. The microRNAs showing greater than 
10-fold upregulation were used for fold change analysis with six ranges: 0–49, 50–99, 100–149, 150–199, 200–249, and 250–300. For the 
analysis of commonly upregulated microRNAs in MDA-MB-231 and CAFs, average fold change values at all RCUs were used.
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and FARP1 (a putative target of miR-3934-5p) were 
downregulated by approximately 80-fold. Target mRNAs 
downregulated by more than 40-fold were TRAM1 (a 
putative target of miR-1225-3p and 3925-5p), LRRC8B 
(a putative target of miR-892c-3p and miR-664a-3p), 
AGPAT3 (a putative target of miR-516b-5p), MMP25 
(a putative target of miR-4769-5p), ZNF331 (a putative 
target of miR-486-5p), KANSL3 (a putative target of miR-
1237-3p), HRK (a putative target of miR-1237-3p), and 
LDOC1L (a putative target of miR-516b-5p) (Figure 3D). 
In CAF1 cells, LPHN3 (a putative target of miR-4656) 
was downregulated by approximately 10-fold (Figure 3E). 
The largest number of downregulated target mRNAs (19) 
was seen in CAF2 cells; CCDC64 (a putative target of 
miR-149-3p) was downregulated to the greatest extent 
(by approximately 25-fold) in these cells. FAM19A2 (a 
putative target of miR-769-3p), GPM6B (a putative target 
of miR-3692-5p), ELAC1 (a putative target of miR-557), 
XKRX (a putative target of miR-4455), and SLC25A15 
(a putative target of miR-3154) were downregulated by 
10- to 20-fold (Figure 3F). In CAF3 cells, nine target 
mRNAs were downregulated. KIAA1211 (a putative 
target of miR-301a-3p) was downregulated by more than 
50-fold. SLC24A2 (a putative target of miR-345-3p), 
SPRR4 (a putative target of miR-4769-5p), and NEDD9 
(a putative target of miR-345-3p) were downregulated by 
Figure 3: Analysis of fold change in expression level of putative target mRNAs of compression-upregulated microRNAs. 
Compression-induced decrease in expression levels of microRNA target genes in A. BT-474, B. MCF7, C. SK-BR-3, D. MDA-MB-231, 
E. CAF1, F. CAF2, G. CAF3, and H. CAF4 cells. Compression-induced target-gene downregulation was analyzed in the same samples of 
total RNA used for microRNA array analysis. Target mRNA downregulation showing more than 5-fold change on average was presented 
for analysis.
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10-fold (Figure 3G). CAF4 cells showed downregulation 
of eight target mRNAs. SCN2B (a putative target of miR-
4455) was downregulated by more than 40-fold. MYL1 (a 
putative target of miR-4455) and KCNJ4 (a putative target 
of miR-4472) were downregulated by approximately 20-
fold (Figure 3H).
Analysis of relationship of compression-
upregulated microRNA target genes to  
tumor progression
Compression induced the upregulation of 
microRNAs in breast cancer cell lines and CAFs, coupled 
with downregulation of putative target mRNAs of the 
microRNAs (Figures 1–3). However, it still remains 
unknown whether compression-induced microRNA 
upregulation is associated with tumor progression. 
To investigate the relationship between compression-
mediated upregulation of microRNAs and tumor 
progression, the proportions of tumor suppression-
associated genes (TSAGs, the genes involved in 
apoptosis, cell adhesion, and cell cycle arrest) and tumor 
promotion-associated genes (TPAGs, the genes involved 
in epithelial-mesenchymal transition [EMT], migration, 
invasion, and angiogenesis) were analyzed among the 
target genes of compression-upregulated microRNAs 
(Figure 4A). Because the primary function of microRNAs 
is to suppress expression of mRNAs, upregulation 
of microRNAs targeting TPAGs may suppress tumor 
progression, whereas upregulation of microRNAs 
targeting TSAGs may contribute to tumor progression by 
blocking apoptosis, cell adhesion, and cell cycle arrest. As 
shown in Figure 4B, among target genes of compression-
upregulated microRNAs, TSAGs represented more than 
25% of genes in all cell types except CAF1, whereas 
TPAGs generally represented less than 15% at the fold 
change cut-off value of 2. At the cut-off value of 5, the 
proportion of TSAGs averaged 30%, whereas TPAGs 
averaged less than 5% in most cells, with the exception 
of BT-474 and SK-BR-3 cells. Among the breast cancer 
cell lines, MDA-MB-231 showed the largest number of 
TSAGs, and MCF-7 showed the smallest. TSAGs with 
greater than 25-fold downregulation were TSPAN7 (a 
putative target of miR4656) in BT-474 cells; HIP1 (a 
putative target of miR-4472) and DLG2 (a putative target 
of miR-3202, miR-4644, and miR-551b-5p) in SK-BR-3 
cells; and HRK (a putative target of miR-4472), ZNF331 
(a putative target of miR-486-5p), and MMP25 (a putative 
target of miR-4769-5p) in MDA-MB-231 cells (Figure 
4C). CAFs did not show many downregulated TSAGs 
compared to the breast cancer cell lines. There were none 
in CAF1 cells, four in CAF2 cells, and two each in CAF3 
and CAF4 cells. The TSAG with greater than 25-fold 
downregulation was SCN2B (a putative target of miR-
4455) in CAF4 cells (Figure 4D). TSAGs and TPAGs for 
each cell type are listed in Supplementary Table S3.
DISCUSSION
MicroRNA array analysis showed that alteration of 
microRNA expression level was induced by compression, 
and to a greater extent in breast cancer cell lines than 
CAFs. Interestingly, the major alteration of compression-
induced microRNA expression was upregulation, not 
downregulation (Figure 1B–1E). To investigate whether 
compression-induced microRNA upregulation contributes 
to tumor progression, fold change in levels of putative 
target mRNAs of compression-upregulated microRNAs 
was analyzed in a parallel mRNA array using the same 
samples of total RNA used for microRNA array. Next, 
downregulated putative target mRNAs were classified 
as TSAGs and TPAGs because the primary function of 
microRNA is to suppress target gene expression [30, 31]. 
As shown in Figure 4B, the portion of TSAGs was much 
higher than that of TPAGs. It was previously reported 
that microRNA-mediated downregulation of TSAGs 
leads to tumor progression; miR-21 overexpression 
contributed to hepatocellular cancer growth and spreading 
via downregulation of PTEN [10]. Pdcd4 suppression by 
miR-21 induced invasion, intravasation, and metastasis of 
colorectal cancer cell lines in chicken-embryo-metastasis 
assay [32]. MicroRNA let-7 suppressed proliferation in a 
lung cancer cell line via HMGA2 suppression [33].
MDA-MB-231 cells showed the largest number of 
compression-upregulated microRNAs (Figure 2D) and 
downregulated TSAGs (Figure 4E and Supplementary 
Figure S2). Manipulation of levels of microRNA 
expression specific to MDA-MB-231 cells may be a 
therapeutic option for incurable cancers. In a mouse 
model of lymphoma, miR-155 antisense RNA slowed 
the growth of pre–B-cell tumors [34]. Ectopic expression 
of miR-133b inhibited the growth of colorectal cancer 
cells (SW-620) in an in vivo tumor xenograft model [35]. 
Restoration of miR-34 expression in pancreatic cancer 
cell line MiaPaCa2 by transfection inhibited clonogenic 
cell growth and invasion, induced apoptosis and cell cycle 
arrest, and sensitized cells to chemo- and radiotherapy 
in vivo [36]. MCF-7 and BT-474 showed less number of 
compression-upregulated microRNA than SK-BR-3 and 
MDA-MB-231 (Figure 2A–2D). These heterogeneous 
responses of breast cancer cells to compression may be 
caused by different expression status of growth factor 
receptors such as ER, PR, and Her2 since membrane-
anchored receptors can function as mechanosensors [37]. 
It was previously reported that ER plays an important role 
in the mechanotransduction of osteocyte and osteoblasts 
[38]. As another example, angiotensin II type 1 receptor 
is known to be activated by mechanical stress without the 
involvement of angiotensin II [39, 40].
Targeting microRNAs expressed in cells of the 
tumor microenvironment may be a good approach. 
Overexpression of miR-148a in CAFs inhibited the 
migration of cells of five endometrial cancer lines [41]. 
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Reconstitution of miR-15 and miR-16 impaired the 
tumor-supportive capability of CAFs [42]. However, 
compression-induced alteration of microRNA expression 
was different between CAFs, which may be caused by 
inter-individual heterogeneity of normal stroma [43]. In 
spite of inter-individual heterogeneity of CAF, targeting 
a compression-upregulate microRNA on CAF may be an 
effective cancer therapy. As shown in Figure 4B, over 25% 
of compression-upregulated microRNAs in CAF2, 3, and 
4 are predicted to target tumor suppressor genes (TSGs). 
Figure 4: Analysis of relationship between compression-upregulated microRNAs and downregulated target genes. 
A. Venn diagram of tumor suppression-associated genes (TSAGs) and tumor promotion-associated genes (TPAGs) among compression-
downregulated target genes. TSAGs include the genes associated with apoptosis, cell adhesion, and cell cycle arrest. TPAGs include 
the genes related to epithelial-mesenchymal transition (EMT), migration, invasion, and angiogenesis. The intersection between TSAGs 
and TPAGs was excluded to avoid confusion. B. Proportional analysis of TSAGs and TPAGs in downregulated putative target genes of 
compression-upregulated microRNAs. The intersection between TSAGs and TPAGs was excluded to avoid confusion. BT, BT-474 cells; 
SK, SK-BR-3 cells; MDA, MDA-MB-231 cells. Inverse correlation between expression of microRNAs and their target genes in C. breast 
cancer cell lines and D. CAFs. Average expression values of microRNAs and target genes were analyzed. Colors of microRNAs are matched 
to those of bars in graph. E. Correlation analysis between the downregulated target genes of compression-upregulated microRNAs, TSAGs, 
and TPAGs. Circos software (version 0.63-9) [49] was used for analysis. Target mRNAs showing upregulation by more than 5-fold on 
average were used in analysis.
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TSG inactivation of CAF is often observed in human 
cancer and increases paracrine signaling to tumor cells via 
cytokine production [44]. miR-4769-5p and miR-4446-3p 
were upregulated by compression in MDA-MB-231 cells 
and CAFs (Figure 2I). Communication between a tumor 
and its microenvironment is crucial for tumor progression 
[45]. Therefore, miR-4769-5p and miR-4446-3p may be 
effective therapeutic targets for incurable cancers because 
they simultaneously downregulate TSAG expression in 
both cancer cells and CAFs, a major component of the 
tumor microenvironment.
In this study, we present the microRNA 
transcriptome-wide analysis of compression-induced 
changes in microRNA expression levels in breast cancer 
cell lines and CAFs treated with different degrees of 
compression. In microRNA array analysis, alteration of 
microRNA expression level was induced by compression, 
and to a greater extent in breast cancer cell lines than 
CAFs. The major alteration of compression-induced 
microRNA expression was upregulation. MDA-MB-231 
cells were the most susceptible to compression in terms 
of changes in microRNA expression level. Finally, miR-
4769-5p and miR4446-3p may be effective therapeutic 
targets for triple negative breast cancer.
MATERIALS AND METHODS
Tissue acquisition
Human breast tumor tissues were obtained from 
four invasive ductal carcinoma (IDC) patients who had 
surgery at Severance Hospital of the Yonsei University 
Health System, South Korea. All patients donating the 
tissues were informed of tissue use for comprehensive 
experiments on breast cancer and provided written 
informed consent. The research protocol was approved by 
the Severance Hospital Ethics Committee (IRB number 
4-2008-0383).
Isolation of CAFs and cell cultures
CAFs were isolated as previously described [46]. 
Briefly, IDC tissues were minced and then digested 
overnight in a collagenase cocktail (ISU ABXIS; Seoul, 
South Korea). Digested tissues were filtered through 
a 70-μm cell strainer (SPL Life Science; Pocheon-
si, South Korea). Cells were separated using Ficoll 
gradients, washed with phosphate-buffered saline (PBS), 
resuspended in Dulbecco’s Modified Eagle medium 
(DMEM)/F12 medium containing 20% (v/v) fetal bovine 
serum (FBS), 100 IU/mL penicillin, and 100 μg/mL 
streptomycin (Gibco BRL; Grand Island, NY, USA), 
and cultured at 37°C in a humidified atmosphere of 5% 
CO2. The fibrotic characteristics of the isolated cells were 
confirmed by microscopic examination of morphology 
and immunofluorescence analysis using antibodies against 
vimentin (Abcam; Cambridge, UK), cytokeratin (Dako; 
Glostrup, Denmark), and cytokeratin 5 (Novocastra; 
Newcastle upon Tyne, UK).
Compression assay and sample preparation
For three-dimensional culture and convenient 
sample preparation, cells were cultured in alginate beads. 
To prepare alginate beads containing cells, pellets of 
BT-474, MCF7, SK-BR-3, and MDA-MB-231 cells 
and CAFs were resuspended in 0.5% alginate solution 
(Sigma-Aldrich; Missouri, USA) at a density of 5 × 
106 cells/mL. Cells suspended in alginate were added 
dropwise into gently stirred 102 mM CaCl2solution for 
polymerization, using a syringe with a 21-gauge needle 
[47]. The cell-alginate beads were washed with PBS 2–3 
times and cultured at 37°C in a humidified atmosphere of 
5% CO2 for 24 h. During this period, the cells stabilized 
and extracellular matrix was deposited around the cells. 
For compression assay, pre-cultured cell-alginate beads 
were embedded in 2% low-melting agarose, equilibrated 
in medium for 1 h, and then relative compression units 
(RCUs) of 0, 0.5, 1, 2, 5, or 10 were applied for 24 h 
using the cube filled with iron beads (Supplementary 
Figure S3). One RCU equals 5.8 mmHg (~0.773 kPa), 
which is the approximate compression value of a native 
tumor microenvironment [23]. An empty cube was loaded 
on agarose-scaffolded alginate beads for the controls 
(0RCU). Compression force transfer to cells via alginate 
beads and agarose gel was evaluated as deformation at 24 
h. Uniaxial deformation to 50% was observed in alginate 
beads and agarose gel. The diffusion rate of nutrients 
can alter gene expression [48]. Since molecular weight 
of almost all nutrients in the media used in our study 
was below 500 Da, nutrient diffusion rate was indirectly 
investigated in 2% agarose gel at different RCUs using 
Ponceau S (approximately 760 Da). The diffusion rate was 
not different in 2% agarose gel compressed at different 
RCUs and in uncompressed 4% agarose gel, which has 
similar pore sizes to those of 50%-deformed 2% agarose 
gel. To regain cells from the alginate beads, beads were 
depolymerized with 55 mM EDTA [47], washed with PBS 
twice, and centrifuged at 250g for 3 min. The cell pellets 
were used immediately or stored at -80°C.
MicroRNA and mRNA arrays
For simultaneous isolation of microRNA and mRNA 
from the same samples, total RNA was extracted from 
uncompressed and compressed BT-474, MCF7, SK-BR-3, 
MDA-MB-231 cells and CAFs using Trizol® (Invitrogen 
Life Technologies; Grand Island, NY, USA). RNA quality 
was assessed using an Agilent 2100 Bioanalyzer (Agilent 
Technologies; Santa Clara, CA, USA), and total RNA 
(OD260/OD230 >1.8; 28s/18s of 1.5; and RNA integrity 
number [RIN] of 7.0) was analyzed on the human 
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microRNA array (Release 19.0, Agilent Technologies) 
and the SurePrint G3 Human Gene expression 8×60K v2 
Microarray (Agilent Technologies). Fold change values 
were calculated as the expression level of a gene at each 
RCU to that at an RCU of 0 (control without compression).
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